2-aminocarbonylcyclopentanone | 62221-86-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-aminocarbonylcyclopentanone
• 英文别名: 2-oxocyclopentane-1-carboxamide；2-oxocyclopentanecarboxamide；2-carbamoyl cyclopentanone；2-carboxamide cyclopentanone；Cyclopentanon-2-carbonsaeureamid
• CAS: 62221-86-7
• 化学式: C₆H₉NO₂
• mdl: MFCD04039713
• 分子量: 127.143
• InChiKey: UEPCFCWEIKTKOZ-UHFFFAOYSA-N

物化性质

• 熔点：
  84 °C
• 沸点：
  98 °C(Press: 0.2 Torr)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  60.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-aminocarbonylcyclopentanone 在 lithium aluminium tetrahydride 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 120.0h， 生成 (1S,2R)-trans-2-(aminomethyl)cyclopentanol
  参考文献：
  名称：

  Bioreduction of 2-oxocyclopentanecarboxamides: syntheses of optically active 2-aminomethyl- and 2-aminocyclopentanols

  摘要：

  The fungus Mortierella isabellina NRRL 1757 catalyzes the reduction of 2-oxocyclopentanecarboxamides with very high enantioselectivity giving, in most cases, the corresponding enantiopure 2-hydroxycyclopentanecarboxamides. The presence or absence of a substituent on the amidic nitrogen has a strong influence on the diastereoselectivity achieved in these processes. Optically active hydroxyamides prepared in these microbial reductions are used as starting materials for the preparation of optically active 2-aminomethyl- and 2-aminocyclopentanols. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00016-6
• 作为产物：
  描述：

  2-diazocyclohexane-1,3-dione 在 六甲基二硅氮烷 作用下， 以 甲苯 为溶剂， 反应 0.05h， 以65%的产率得到2-aminocarbonylcyclopentanone
  参考文献：
  名称：

  将甲硅烷基亲核试剂添加到[小α]-氧杂环丁烯酮中

  摘要：

  提出了甲硅烷基化的亲核试剂截获由微波辅助的2-重氮-1,3-二羰基化合物的沃尔夫夫重排产生的瞬变α-氧代酮的一般评价。可以快速，快速地访问原始脚手架和合成中间体。

  DOI：

  10.1039/c5cc10217k

文献信息

• Fe(III) Complex Compounds For The Treatment And Prophylaxis Of Iron Deficiency Symptoms And Iron Deficiency Anemias
  申请人：Bark Thomas

  公开号：US20130109662A1

  公开（公告）日：2013-05-02

  The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

  这项发明涉及铁（III）配合物和包括它们的药物组合物，用作药物，特别是用于治疗和/或预防缺铁症状和缺铁性贫血。
• Lipase-catalyzed aminolysis and ammonolysis of β-ketoesters. Synthesis of optically active β-ketoamides.
  作者：María Jesús García、Francisca Rebolledo、Vicente Gotor

  DOI：10.1016/s0040-4020(01)81346-6

  日期：1994.1

  Aminolysis and ammonolysis reactions of β-ketoesters catalysed by Candida antarctica lipase are very efficient methods for the preparation of β—ketoamides. When racemic amines are used in these processes, the corresponding optically active β—ketoamides are obtained with moderate-high enantiomeric excesses.

  南极假丝酵母脂肪酶催化的β-酮酯的氨解和氨解反应是制备β-酮酰胺的非常有效的方法。当在这些方法中使用外消旋胺时，可获得具有适度高对映体过量的相应旋光性β-酮酰胺。
• Sulfur containing diamides and antimicrobial use
  申请人：Imperial Chemical Industries PLC

  公开号：US05224980A1

  公开（公告）日：1993-07-06

  A compound of the formula ##STR1## in which R.sup.1 and R.sup.2 taken together, and R.sup.3 and R.sup.4 taken together, independently represent a polymethylene chain having 3 or 4 carbon atoms, or a polymethylene chain having 3 or 4 carbon atoms substituted by at least one lower alkyl radical having from 1 to 4 carbon atoms, and R.sup.5 to R.sup.8 are independently hydrogen, hydrocarbyl or substituted hydrocarbyl. Typically R.sup.1 and R.sup.2 and also R.sup.3 and R.sup.4 complete a trimethylene ring, R.sup.5 and R.sup.7 are each hydrogen and R.sup.6 and R.sup.8 are alkyl such as methyl. The compounds have microbiological activity.

  该化合物的化学式为##STR1## 其中R.sup.1和R.sup.2一起取，R.sup.3和R.sup.4一起取，独立地代表具有3或4个碳原子的聚亚甲基链，或具有3或4个碳原子的聚亚甲基链，其上至少有一个低碳基基团，其碳原子数为1至4，而R.sup.5到R.sup.8独立地代表氢，烃基或取代烃基。通常情况下，R.sup.1和R.sup.2以及R.sup.3和R.sup.4共同构成三亚甲基环，R.sup.5和R.sup.7分别为氢，而R.sup.6和R.sup.8为烷基，例如甲基。这些化合物具有微生物活性。
• Process for the preparation of a 4,5-tri or
  申请人：Centre International de Recherches Dermatologiques (C.I.R.D.)

  公开号：US04851541A1

  公开（公告）日：1989-07-25

  A process for preparing a 4,5-tri or tetramethylene-4-isothiazoline-3-one comprises cyclizing a 2-alkyl or aralkyl thio-1-cycloalkene-1-carboxamide in the form of its sulfoxide in an organic solvent in the presence of a acid chloride and adding to the resulting 4,5-tri or tetramethylene-4-isothiazoline-3-one hydrochloride a mineral or organic base or water so as to free the 4,5-tri or tetramethylene-4-isothiazoline-3-one in the form of a free base.

  一种制备4,5-三或四亚甲基-4-异噻唑啉-3-酮的方法，包括在有机溶剂中存在酸性氯化物的情况下，使2-烷基或芳基烷基硫代-1-环己烯-1-羧酰胺的亚砜环化，并向所得的4,5-三或四亚甲基-4-异噻唑啉-3-酮盐酸中加入矿物质或有机碱或水，以释放4,5-三或四亚甲基-4-异噻唑啉-3-酮的游离碱形式。
• Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
  申请人：Zhong Wenge

  公开号：US20090275602A1

  公开（公告）日：2009-11-05

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I or Formula II wherein R 1a , R 1b , R 1c , B, R 3 , R 4 , R 5 and W of Formula I, and R 1a , R 1b , R 1c , R 2 , R 2a , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , W, X, Z, m and n of Formula II are defined herein. The invention also provides compounds of Formula III, sub-Formulas II-A-II-D, sub-Formulas III-A-III-D and Formula IV. The invention further includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, AD, cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formulas I, II, III, IV and sub-formulas thereof, intermediates and processes useful for the preparation of compounds of Formulas I, II, III, IV and sub-formulas thereof.

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性以及治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施方式中，该化合物具有一般的I式或II式，其中I式中的R1a、R1b、R1c、B、R3、R4、R5和W，以及II式中的R1a、R1b、R1c、R2、R2a、R3、R4、R5、A1、A2、A3、A4、W、X、Z、m和n在此定义。本发明还提供了III式、子式II-A-II-D、子式III-A-III-D和IV式的化合物。本发明还包括将这些化合物用于制备药物组合物，用于治疗、预防或治疗与β-分泌酶蛋白活性相关的疾病和病况，例如AD、认知缺陷和障碍、精神分裂症和其他类似的中枢神经系统疾病。本发明还涉及I、II、III、IV式及其子式的进一步实施方式，以及制备I、II、III、IV式及其子式的化合物的中间体和过程。